Gemcitabine and carboplatin in carcinoma of unknown primary site: A phase 2 Adelaide Cancer Trials and Education Collaborative study

British Journal of Cancer

Volumn 95, Issue 10, 2006, Pages 1309-1313

  Pittman, K B ^a   Olver, I N ^b   Koczwara, B ^c   Kotasek, D ^d   Patterson, W K ^a   Keefe, D M ^b   Karapetis, C S ^c   Parnis, F X ^d   Moldovan, S ^a   Yeend, S J ^a   Price, T J ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d Ashford Hospital   (Australia)

Author keywords

Carboplatin; Carcinoma of unknown primary; Elderly; Gemcitabine

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOLOGY; HUMAN; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CARBOPLATIN; CARCINOMA, LARGE CELL; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33751063295     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603440     Document Type: Article

References (16)

1. Briasoulis E, Kalofonos H, Bafaloukas D, Samantas E, Fountzilas G, Xiros N, Christodoulou C, Kosmidis P (2000) Carboplatin plus paclitaxel in unknown primary cancer: a phase 2 Hellenic co-operative oncology group study. J Clin Oncol 18: 3101-3107
2. Calvert H, Newell D, Gumbrell L (1989) Carboplatin dosage: a prospective evaluation of a simple formula based upon renal function. J Clin Oncol 7: 1748-1756
3. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizari K (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of unknown primary site. J Clin Oncol 20: 4679-4683
4. Culine S, Loertholary A, Voigt J, Bugat R, Theodore C, Priou F, Kaminsky M, Lesimple T, Pivot X, Coudert B, Douillard J, Merrouche Y, Allouache A, Goupil A, Negrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomised phase II study - Trial of the French Study Group on carcinomas of unknown primary (GEFCAPI). J Clin Oncol 21: 3479-3482
5. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
6. Greco F, Burris H, Litchy S, Barton J, Bradof J, Richards P, Scullin D, Erland J, Morrissey L, Hainsworth J (2002) Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 20: 1651-1656
7. Greco F, Hainsworth J (2001) Cancer of unknown primary site. In: Cancer; Principles and Practice of Oncology De Vita V, Hellman S, Rosenberg S (eds), 6th edn, pp 2537-2560. Philadelphia: Lippincott
8. Langer C, Calvert P, Ozols R (1998) Gemcitabine and carboplatin in combination: phase 1 and 2 studies. Semin Oncol 25(4, Suppl 9): 51-54
9. Lenzi R, Hess K, Abbruzzese M, Raber M, Ordonez N, Abbruzzese J (1997) Poorly differentiated carcinoma and poorly differentiated carcinoma of unknown origin: favourable subsets of patients with unknown primary carcinoma? J Clin Oncol 15: 2056-2066
10. Linardou H, Aravantinos G, Efstathious E, Kalafonos C, Anagnostopoulos A, Delveliotis C, Bafaloukos D, Athanasios Dimoloulos M, Bamias A (2004) Gemcitabine and carboplatin as first line treatment in elderly patients and those unfit for cisplatin based chemotherapy with advanced bladder carcinoma: a phase 2 study of the Hellenic co-operative oncology group. Urology 64: 479-484
11. Miller A, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
12. Park Y, Ryoo B, Choi S, Yang S, Kim H (2004) A phase 2 study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 34: 681-685
13. Parnis F, Olver I, Kotasek D, Norman J, Taylor A, Russell J, Patterson K, Keefe D, Marafioti T (2000) Phase 2 study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Ann Oncol 11: 883-884
14. Pfisterer J, Vergote I, Du Bois A, Eisenhuer E (2005) Combination chemotherapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynaecol Cancer 15(Suppl 1): 36-41
15. Sedeholm C, Hillerdal G, Lamberg K, Kolbeck K, Dufmats M, Westberg R, Gawande S (2005) Phase 3 trial of gemcitabine plus carboplatin versus single agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 23: 8380-8388
16. Sporn J, Greenberg B (1993) Empirical therapy for adenocarcinoma of unknown primary tumor site. Semin Oncol 20: 261-270